HaemaLogiX Presents Updates on Novel Therapeutic Targets

During the 22nd International Myeloma Society (IMS) Annual Meeting & Exposition, held 14 – 17 September 14 17 2025 in Toronto, Canada, HaemaLogiX, a clinical-stage Australian biotechnology company advancing a pipeline of next-generation immunotherapies for blood cancers and B-cell disorders, presented clinical updates on novel therapeutic targets Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA).

HaemaLogiX’s innovative immunotherapies effectively direct the immune system to destroy cancerous cells while minimising harm to normal plasma cells.

The research highlighted several key findings:

1. KMA and LMA are present on bone marrow plasma cells in the majority of cases of plasma cell dyscrasias of all types and represent a potentially valuable target for immunotherapy
2. In myeloma patients treated with standard of care therapies, both KMA and LMA expression were increased on malignant plasma cells compared to BCMA, suggesting that our immunotherapies would also be effective in patients who don’t respond to myeloma treatments
3. Targeting KMA or LMA may leave alternative isotype plasma cells intact, reduce infectious complications, and retain vaccine responsiveness after immunotherapy

Innovative immunotherapies
This research underscores the potential of HaemaLogiX’s innovative immunotherapies, KappaMab and LambdaMab, which are designed to specifically target KMA or LMA on the surface of malignant plasma cells, effectively directing the immune system to destroy these cancerous cells while minimizing harm to normal plasma cells.

“In this poster, we highlighted findings that Kappa and Lambda Myeloma Antigens are consistently expressed on malignant plasma cells across a range of plasma cell dyscrasias, but not on normal plasma cells. This demonstrates their potential as highly-specific targets for immunotherapy – offering a promising pathway to treat disease while preserving normal immune function,” noted Rosanne Dunn, Ph.D., Chief Scientific Officer, co-founder and Executive Director at HaemaLogiX.

Reference
[1] Sartor M, Lemarchand TX, Britz L, Erc J, Harrison SJ, Dunn R, and Gottlieb DJ. Novel therapeutic targets Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA) are expressed on malignant plasma cells from patients with plasma cell dyscrasias but not on normal plasma cells.During the 22nd International Myeloma Society (IMS) Annual Meeting & Exposition, held 14 – 17 September 14 17 2025 in Toronto, Canada.

Featured image: Rosanne Dunn, Ph.D., Chief Scientific Officer and Executive Director at HaemaLogiX.Photo courtesy © 2025 HaemaLogiX. Used with permission.

DOI